401 results on '"Lalezari, P."'
Search Results
2. Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
- Author
-
Samsom, Kris G., Bosch, Linda J. W., Schipper, Luuk J., Schout, Daoin, Roepman, Paul, Boelens, Mirjam C., Lalezari, Ferry, Klompenhouwer, Elisabeth G., de Langen, Adrianus J., Buffart, Tineke E., van Linder, Berit M. H., van Deventer, Kelly, van den Burg, Kay, Unmehopa, Unga, Rosenberg, Efraim H., Koster, Roelof, Hogervorst, Frans B. L., van den Berg, José G., Riethorst, Immy, Schoenmaker, Lieke, van Beek, Daphne, de Bruijn, Ewart, van der Hoeven, Jacobus J. M., van Snellenberg, Hans, van der Kolk, Lizet E., Cuppen, Edwin, Voest, Emile E., Meijer, Gerrit A., and Monkhorst, Kim
- Published
- 2024
- Full Text
- View/download PDF
3. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses
- Author
-
Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T. Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G. Nahass, James S. Park, Ira M. Jacobson, Walid S. Ayoub, Steven-Huy Han, Edward J. Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J. Knox, Luisa M. Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T. Dieterich, Paul Yien Kwo, Eugene R. Schiff, Ho S. Bae, Jacob Lalezari, Kosh Agarwal, and Mark S. Sulkowski
- Subjects
Hepatitis ,Core inhibitor ,Antiviral ,Off-treatment ,Open-label ,Nucleos(t)ide reverse transcriptase inhibitor ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In this long-term extension study, patients received open-label VBR with nucleos(t)ide reverse transcriptase inhibitors (NrtIs). Methods: Patients in this study (NCT03780543) previously received VBR + NrtI or placebo + NrtI in parent studies 201 (NCT03576066) or 202 (NCT03577171). After receiving VBR + NrtI for ≥52 weeks, stopping criteria (based on the treatment history and hepatitis B e antigen status in the parent studies) were applied, and patients either discontinued both VBR + NrtI, discontinued VBR only, or continued both VBR + NrtI. The primary efficacy endpoint was the proportion of patients with HBV DNA
- Published
- 2024
- Full Text
- View/download PDF
4. Pregnancy outcomes in women with a mitral valve prosthesis: A systematic review and meta-analysisCentral MessagePerspective
- Author
-
Pepijn Grashuis, BSc, Shanti D.M. Khargi, BSc, Kevin Veen, BSc, PhD, Azzeddine el Osrouti, BSc, Shirin Bemelmans-Lalezari, MD, PhD, Jérôme M.J. Cornette, MD, PhD, Jolien W. Roos-Hesselink, MD, PhD, Johanna J.M. Takkenberg, MD, PhD, and Mostafa M. Mokhles, MD, PhD
- Subjects
mitral valve replacement ,pregnancy ,bioprosthesis ,mechanical valve ,oral anticoagulant ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Surgery ,RD1-811 - Abstract
Objectives: To evaluate the ongoing debate concerning the choice of valve prosthesis for women requiring mitral valve replacement (MVR) and who wish to conceive. Bioprostheses are associated with risk of early structural valve deterioration. Mechanical prostheses require lifelong anticoagulation and carry maternal and fetal risks. Also, the optimal anticoagulation regimen during pregnancy after MVR remains unclear. Methods: A systematic review and meta-analysis was conducted of studies reporting on pregnancy after MVR. Valve- and anticoagulation-related maternal and fetal risks during pregnancy and 30 days’ postpartum were analyzed. Results: Fifteen studies reporting 722 pregnancies were included. In total, 87.2% of pregnant women had a mechanical prosthesis and 12.5% a bioprosthesis. Maternal mortality risk was 1.33% (95% confidence interval [CI], 0.69-2.56), any hemorrhage risk 6.90% (95% CI, 3.70-12.88). Valve thrombosis risk was 4.71% (95% CI, 3.06-7.26) in patients with mechanical prostheses. 3.23% (95% CI, 1.34-7.75) of the patients with bioprostheses experienced early structural valve deterioration. Of these, the mortality was 40%. Pregnancy loss risk was 29.29% (95% CI, 19.74-43.47) with mechanical prostheses versus 13.50% (95% CI, 4.31-42.30) for bioprostheses. Switching to heparin during the first trimester demonstrated a bleeding risk of 7.78% (95% CI, 3.71-16.31) versus 4.08% (95% CI, 1.17-14.28) for women on oral anticoagulants throughout pregnancy and a valve thrombosis risk of 6.99% (95% CI, 2.08-23.51) versus 2.89% (95% CI, 1.40-5.94). Administration of anticoagulant dosages greater than 5 mg resulted in a risk of fetal adverse events of 74.24% (95% CI, 56.11-98.23) versus 8.85% (95% CI, 2.70-28.99) in ≤5 mg. Conclusions: A bioprosthesis seems the best option for women of childbearing age who are interested in future pregnancy after MVR. If mechanical valve replacement is preferred, the favorable anticoagulation regimen is continuous low-dose oral anticoagulants. Shared decision-making remains priority when choosing a prosthetic valve for young women.
- Published
- 2023
- Full Text
- View/download PDF
5. Altered abundances of human immunoglobulin M and immunoglobulin G subclasses in Alzheimer’s disease frontal cortex
- Author
-
Rukmani Lekhraj, Shirin Lalezari, Jennifer T. Aguilan, Jiyue Qin, Simone Sidoli, Wenzhu Mowrey, Seema Gollamudi, and Parviz Lalezari
- Subjects
Medicine ,Science - Abstract
Abstract The immune system has been described to play a role in the development of Alzheimer’s disease (AD), but the distribution of immunoglobulins and their subclasses in brain tissue has not been explored. In this study, examination of pathologically diagnosed frontal cortex gray matter revealed significantly higher levels of IgM and IgG in late-stage AD (Braak and Braak stages V and VI) compared to age-matched controls. While levels of IgG2 and IgG4 constant region fragments were higher in late-stage AD, concentration of native–state IgG4 with free Fc regions was increased in AD III and VI. RNA analysis did not support parenchymal B-cell production of IgG4 in AD III and V, indicating possible peripheral or meningeal B-cell involvement. Changes in the profile of IgM, IgG and IgG subclasses in AD frontal cortex may provide insight into understanding disease pathogenesis and progression.
- Published
- 2022
- Full Text
- View/download PDF
6. A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic.
- Author
-
Diamond, Shawn, Lundy, Jonathan B, Weber, Erin L, Lalezari, Shadi, Rafijah, Gregory, Leis, Amber, Gray, Benjamin L, Lin, Ines C, and Gupta, Ranjan
- Subjects
COVID-19 ,Coronavirus ,Extremity trauma ,Hand and upper-extremity emergencies ,Replantation ,Neurosciences ,Clinical Research ,Physical Injury - Accidents and Adverse Effects ,Patient Safety ,Good Health and Well Being - Abstract
PurposeLimited data exist regarding volumetric trends and management of upper-extremity emergencies during periods of social restriction and duress, such as the coronavirus disease 2019 pandemic. We sought to study the effect of shelter-in-place orders on emergent operative upper-extremity surgery.MethodsAll patients undergoing emergent and time-sensitive operations to the finger(s), hand, wrist, and forearm were tracked over an equal number of days before and after shelter-in-place orders at 2 geographically distinct Level I trauma centers. Surgical volume and resources, patient demographics, and injury patterns were compared before and after official shelter-in-place orders.ResultsA total of 58 patients underwent time-sensitive or emergent operations. Mean patient age was 42 years; mean injury severity score was 9 and median American Society of Anesthesiologist score was 2. There was a 40% increase in volume after shelter-in-place orders, averaging 1.4 cases/d. Indications for surgery included high-energy closed fracture (60%), traumatic nerve injury (19%), severe soft tissue infection (15%), and revascularization of the arm, hand, or digit(s) (15%). High-risk behavior, defined as lawlessness, assault, and high-speed auto accidents, was associated with a significantly greater proportion of operations after shelter-in-place orders (40% vs 12.5%; P < .05). Each institution dedicated an average of 3 inpatient beds and one intensive care unit-capable bed to upper-extremity care daily. Resources used included an average of 115 minutes of daily operating room time and 8 operating room staff or personnel per case.ConclusionsHand and upper-extremity operative volume increased after shelter-in-place orders at 2 major Level I trauma centers across the country, demanding considerable hospital resources. The rise in volume was associated with an increase in high-risk behavior.Type of study/level of evidenceTherapeutic IV.
- Published
- 2020
7. Altered abundances of human immunoglobulin M and immunoglobulin G subclasses in Alzheimer’s disease frontal cortex
- Author
-
Lekhraj, Rukmani, Lalezari, Shirin, Aguilan, Jennifer T., Qin, Jiyue, Sidoli, Simone, Mowrey, Wenzhu, Gollamudi, Seema, and Lalezari, Parviz
- Published
- 2022
- Full Text
- View/download PDF
8. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: analysis from the PROTECT VIII study
- Author
-
Mark T. Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, and Cedric Hermans
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to date on efficacy and safety of treatment specifically in patients with severe haemophilia A and comorbidities. Objective: To explore the efficacy and safety of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A aged ⩾40 years with comorbidities of interest. Design: A post hoc analysis of data from the phase 2/3 PROTECT VIII study and its extension. Methods: Bleeding and safety outcomes were analysed in a subgroup of patients aged ⩾40 years with ⩾1 comorbidity receiving damoctocog alfa pegol (BAY 94-9027; Jivi ® ) prophylaxis. Results: Thirty-four patients with severe haemophilia A were included in this analysis, with a mean age of 49.4 years at time of enrolment. The most prevalent comorbidities were hepatitis C ( n = 33; chronic, n = 23), hepatitis B ( n = 8) and hypertension ( n = 11). Four patients had human immunodeficiency virus. All received damoctocog alfa pegol prophylaxis for the entire study [median (range) time in study = 3.9 (1.0–6.9) years]. During the main study and extension, median total annualised bleeding rates (ABRs) (Q1; Q3) were 2.1 (0.0; 5.8) and 2.2 (0.6; 6.0), respectively; median joint ABRs were 1.9 (0.0; 4.4) and 1.6 (0.0; 4.0), respectively. Mean adherence with prophylaxis schedule was greater than 95% throughout the study. No deaths or thrombotic events were reported. Conclusion: Efficacy, safety and adherence of damoctocog alfa pegol were confirmed in patients aged ⩾40 years with haemophilia A and one or more comorbidities, with data for up to 7 years supporting its use as a long-term treatment option in this group.
- Published
- 2023
- Full Text
- View/download PDF
9. The effects of ceiling display and natural sounds on stress and anxiety among cardiac patients: A randomized controlled trial
- Author
-
Roghayeh Lalezari, Roghayeh Mehdipour-Rabori, Tania Dehesh, and Esmat Nouhi
- Subjects
anxiety ,ceiling display ,heart disease ,sounds of nature ,stress ,Nursing ,RT1-120 - Abstract
Background: Cardiovascular disease is the most common chronic disease and the leading cause of death in the world. Stress and anxiety are among the most important risk factors of cardiovascular disease. Objectives: The aim of this study was to assess the effects of ceiling display and natural sounds on stress and anxiety among cardiac patients. Methods: This randomized controlled trial was conducted in 2018–2019 in the coronary care units (CCUs) of two teaching hospitals affiliated to Kerman University of Medical Sciences, Kerman, Iran. Participants were 220 cardiac patients randomly allocated through block randomization to four 55-person groups, namely ceiling display group, natural sounds group, combined ceiling display and natural sounds (display sound) group, and control group. The Spielberger State-Trait Anxiety Inventory and the Perceived Stress Scale were used for data collection at the beginning of the study and at the time of discharge from CCU. Data were analyzed by the Chi-square and paired-sample t-tests and the analysis of variance. Results: The mean scores of state and trait anxiety and stress significantly decreased in all intervention groups (P < 0.05) and did not significantly change in the control group (P > 0.05). There were significant differences among the groups respecting the posttest mean scores of state and trait anxiety and stress (P < 0.05). The posttest mean scores of state and trait anxiety in the combined display-sound group and the posttest mean scores of stress in the natural sounds group were significantly less than other groups. Conclusion: Ceiling display and natural sounds are effective in significantly reducing state and trait anxiety and stress among cardiac patients in CCU and their combination produces more significant effects.
- Published
- 2022
- Full Text
- View/download PDF
10. Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
- Author
-
Rima Dardik, Szymon Janczar, Shadan Lalezari, Einat Avishai, Sarina Levy-Mendelovich, Assaf Arie Barg, Uri Martinowitz, Katarzyna Babol-Pokora, Wojciech Mlynarski, and Gili Kenet
- Subjects
hemophilia A ,factor VIII ,F8 gene ,carrier detection ,prenatal diagnosis ,preimplantation genetic diagnosis ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Hemophilia A (HA), a rare recessive X-linked bleeding disorder, is caused by either deficiency or dysfunction of coagulation factor VIII (FVIII) resulting from deleterious mutations in the F8 gene encoding FVIII. Over the last 4 decades, the methods aimed at determining the HA carrier status in female relatives of HA patients have evolved from phenotypic studies based on coagulation tests providing merely probabilistic results, via genetic linkage studies based on polymorphic markers providing more accurate results, to next generation sequencing studies enabling highly precise identification of the causative F8 mutation. In parallel, the options for prenatal diagnosis of HA have progressed from examination of FVIII levels in fetal blood samples at weeks 20–22 of pregnancy to genetic analysis of fetal DNA extracted from chorionic villus tissue at weeks 11–14 of pregnancy. In some countries, in vitro fertilization (IVF) combined with preimplantation genetic diagnosis (PGD) has gradually become the procedure of choice for HA carriers who wish to prevent further transmission of HA without the need to undergo termination of pregnancies diagnosed with affected fetuses. In rare cases, genetic analysis of a HA carrier might be complicated by skewed X chromosome inactivation (XCI) of her non-hemophilic X chromosome, thus leading to the phenotypic manifestation of moderate to severe HA. Such skewed XCI may be associated with deleterious mutations in X-linked genes located on the non-hemophilic X chromosome, which should be considered in the process of genetic counseling and PGD planning for the symptomatic HA carrier. Therefore, whole exome sequencing, combined with X-chromosome targeted bioinformatic analysis, is highly recommended for symptomatic HA carriers diagnosed with skewed XCI in order to identify additional deleterious mutations potentially involved in XCI skewing. Identification of such mutations, which may profoundly impact the reproductive choices of HA carriers with skewed XCI, is extremely important.
- Published
- 2023
- Full Text
- View/download PDF
11. Nursing and Midwifery Students’ Mental Health Status and Intention to Leave During Covid-19 Pandemic
- Author
-
Hamidreza Haririan PhD, Parisa Samadi BSc, Elnaz Lalezari BSc, Sajad Habibzadeh MsN, and Joanne E Porter PhD
- Subjects
Nursing ,RT1-120 - Abstract
Introduction COVID-19 has not only affected the physical health of people but it has also had a major impact on their mental health. Objective To investigate the nursing, midwifery, and operating room students’ mental health and intention to leave during COVID-19 pandemic. Methods This cross-sectional study was conducted at the nursing and midwifery school of Tabriz, Iran. Over a period of three months (February–May 2021) and through random sampling, 284 students were selected. The research tool consisted of three parts including demographic information, Depression Anxiety Stress scales, and a questionnaire on intention to leave. Results More than 20% of the students experienced some degrees of depression, anxiety, and stress. Nearly one-third of participants mentioned a high level of intention to leave. Nursing students had a higher level of a turnover tendency than other students ( p = .004). Male students and who experienced moderate to high level of depression displayed greater intention to leave ( p = .005). Conclusion Students suffered from some degrees of stress, anxiety, and depression during the COVID-19, and it strengthened the participants’ intention to leave. Relevant authorities are recommended to improve mental health of the students by providing psychological counseling sessions, reducing their direct contact with patients, and providing personal protective equipment.
- Published
- 2022
- Full Text
- View/download PDF
12. MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
- Author
-
M.W. Rohaan, R. Gomez-Eerland, J.H. van den Berg, M.H. Geukes Foppen, M. van Zon, B. Raud, I. Jedema, S. Scheij, R. de Boer, N.A.M. Bakker, D. van den Broek, L.M. Pronk, L.G. Grijpink-Ongering, A. Sari, R. Kessels, M. van den Haak, H.A. Mallo, M. Karger, B.A. van de Wiel, C.L. Zuur, C.W. Duinkerken, F. Lalezari, J.V. van Thienen, S. Wilgenhof, C.U. Blank, J.H. Beijnen, B. Nuijen, T.N. Schumacher, and J.B.A.G. Haanen
- Subjects
adoptive cell therapy ,immunotherapy ,MART-1 ,melanoma ,T-cell receptor gene therapy ,uveal ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Adoptive cell therapy with peripheral blood T cells expressing transgenic T-cell receptors (TCRs) is an innovative therapeutic approach for solid malignancies. We investigated the safety and feasibility of adoptive transfer of autologous T cells expressing melanoma antigen recognized by T cells 1 (MART-1)-specific TCR, cultured to have less differentiated phenotypes, in patients with metastatic melanoma. Materials and methods: In this phase I/IIa trial, peripheral blood T cells from HLA-A2∗02:01-positive patients with unresectable stage IIIC/IV melanoma expressing MART-1 were selected and stimulated with anti-CD3/CD28 beads, transduced with a modified MART-1(26-35)-specific 1D3 TCR (1D3HMCys) and expanded in interleukin (IL)-7 and IL-15. Patients received a single infusion of transgenic T cells in a dose-escalating manner. Feasibility, safety and objective response rate were assessed. Results: Twelve pretreated metastatic cutaneous (n = 7) and uveal (n = 5) melanoma patients were included. Patient 1 received 4.6 × 109 1D3HMCys T cells and experienced grade 5 toxicity after 9 days. Subsequent patients received 5.0 × 107 [n = 3; cohort (c) 2], 2.5 × 108 (n = 2; c3) and 1.0 × 108 (n = 6; c4) 1D3HMCys T cells. The study was prematurely terminated because of dose-dependent toxicity, concerning skin (10/12), eyes (3/12), ears (4/12) and cytokine release syndrome (5/12), with 7 patients experiencing grade 3-5 toxicity. Partial responses were seen in 2/11 (18%) assessable patients and persistence of 1D3HMCys T cells corresponded to infused cell dose. Conclusions: Production of TCR-modified cells as described leads to highly potent T cells. Partial responses were seen in 18% of patients with dose-dependent ‘on-target, off-tumor’ toxicity and a maximum tolerated dose of 1.0 × 108 cells.
- Published
- 2022
- Full Text
- View/download PDF
13. Real-World data of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place
- Author
-
A. Bex, N. Graafland, A. Meerveld-Eggink, S. Wilgenhof, J. Van Thienen, F. Lalezari, M. Grant, B. Szabados, Y. Abu-Ghanem, T. Kuusk, E. Boleti, C. Blank, T. Powles, and J. Haanen
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2022
- Full Text
- View/download PDF
14. Deconstructing negative pressure wound therapy
- Author
-
Lalezari, Shadi, Lee, Christine J, Borovikova, Anna A, Banyard, Derek A, Paydar, Keyianoosh Z, Wirth, Garrett A, and Widgerow, Alan D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Physical Injury - Accidents and Adverse Effects ,Skin ,Adult ,Aged ,Aged ,80 and over ,Chronic Disease ,Female ,Humans ,Male ,Middle Aged ,Negative-Pressure Wound Therapy ,Wound Healing ,Wounds and Injuries ,Exudate control ,Macrodeformation ,Microdeformation ,Negative pressure wound therapy ,Perfusion changes ,Nursing ,Dermatology & Venereal Diseases ,Clinical sciences - Abstract
Since its introduction 20 years ago for the treatment of chronic wounds, negative pressure wound therapy use has expanded to a variety of other wound types. Various mechanisms of action for its efficacy in wound healing have been postulated, but no unifying theory exists. Proposed mechanisms include induction of perfusion changes, microdeformation, macrodeformation, exudate control and decreasing the bacterial load in the wound. We surmise that these different mechanisms have varying levels of dominance in each wound type. Specifically, negative pressure wound therapy is beneficial to acute open wounds because it induces perfusion changes and formation of granulation tissue. Post-surgical incisional wounds are positively affected by perfusion changes and exudate control. In the context of chronic wounds, negative pressure wound therapy removes harmful and corrosive substances within the wounds to affect healing. When skin grafts and dermal substitutes are used to close a wound, negative pressure wound therapy is effective in promoting granulation tissue formation, controlling exudate and decreasing the bacterial load in the wound. In this review, we elucidate some of the mechanisms behind the positive wound healing effects of negative pressure wound therapy, providing possible explanations for these effects in different wound types.
- Published
- 2017
15. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14
- Author
-
Bruce K. Patterson, Harish Seethamraju, Kush Dhody, Michael J. Corley, Kazem Kazempour, Jay Lalezari, Alina P.S. Pang, Christopher Sugai, Eisa Mahyari, Edgar B. Francisco, Amruta Pise, Hallison Rodrigues, Helen L. Wu, Gabriela M. Webb, Byung S. Park, Scott Kelly, Nader Pourhassan, Alina Lelic, Lama Kdouh, Monica Herrera, Eric Hall, Benjamin N. Bimber, Matthew Plassmeyer, Raavi Gupta, Oral Alpan, Jane A. O’Halloran, Philip A. Mudd, Enver Akalin, Lishomwa C. Ndhlovu, and Jonah B. Sacha
- Subjects
COVID-19 ,Immunotherapy ,Plasma viral load ,CCR5 ,Leronlimab ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objective: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic. Emerging results indicate a dysregulated immune response. Given the role of CCR5 in immune cell migration and inflammation, we investigated the impact of CCR5 blockade via the CCR5-specific antibody leronlimab on clinical, immunological, and virological parameters in severe COVID-19 patients. Methods: In March 2020, 10 terminally ill, critical COVID-19 patients received two doses of leronlimab via individual emergency use indication. We analyzed changes in clinical presentation, immune cell populations, inflammation, as well as SARS-CoV-2 plasma viremia before and 14 days after treatment. Results: Over the 14-day study period, six patients survived, two were extubated, and one discharged. We observed complete CCR5 receptor occupancy in all donors by day 7. Compared with the baseline, we observed a concomitant statistically significant reduction in plasma IL-6, restoration of the CD4/CD8 ratio, and resolution of SARS-CoV2 plasma viremia (pVL). Furthermore, the increase in the CD8 percentage was inversely correlated with the reduction in pVL (r = −0.77, p = 0.0013). Conclusions: Our study design precludes clinical efficacy inferences but the results implicate CCR5 as a therapeutic target for COVID-19 and they form the basis for ongoing randomized clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
16. Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.
- Author
-
Xiao L Chang, Jason S Reed, Gabriela M Webb, Helen L Wu, Jimmy Le, Katherine B Bateman, Justin M Greene, Cleiton Pessoa, Courtney Waytashek, Whitney C Weber, Joseph Hwang, Miranda Fischer, Cassandra Moats, Oriene Shiel, Rachele M Bochart, Hugh Crank, Don Siess, Travis Giobbi, Jeffrey Torgerson, Rebecca Agnor, Lina Gao, Kush Dhody, Jacob P Lalezari, Ivo Sah Bandar, Alnor M Carnate, Alina S Pang, Michael J Corley, Scott Kelly, Nader Pourhassan, Jeremy Smedley, Benjamin N Bimber, Scott G Hansen, Lishomwa C Ndhlovu, and Jonah B Sacha
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
The CCR5-specific antibody Leronlimab is being investigated as a novel immunotherapy that can suppress HIV replication with minimal side effects. Here we studied the virological and immunological consequences of Leronlimab in chronically CCR5-tropic HIV-1 infected humans (n = 5) on suppressive antiretroviral therapy (ART) and in ART-naïve acutely CCR5-tropic SHIV infected rhesus macaques (n = 4). All five human participants transitioned from daily combination ART to self-administered weekly subcutaneous (SC) injections of 350 mg or 700 mg Leronlimab and to date all participants have sustained virologic suppression for over seven years. In all participants, Leronlimab fully occupied CCR5 receptors on peripheral blood CD4+ T cells and monocytes. In ART-naïve rhesus macaques acutely infected with CCR5-tropic SHIV, weekly SC injections of 50 mg/kg Leronlimab fully suppressed plasma viremia in half of the macaques. CCR5 receptor occupancy by Leronlimab occurred concomitant with rebound of CD4+ CCR5+ T-cells in peripheral blood, and full CCR5 receptor occupancy was found in multiple anatomical compartments. Our results demonstrate that weekly, self-administered Leronlimab was safe, well-tolerated, and efficacious for long-term virologic suppression and should be included in the arsenal of safe, easily administered, longer-acting antiretroviral treatments for people living with HIV-1. Trial Registration: ClinicalTrials.gov Identifiers: NCT02175680 and NCT02355184.
- Published
- 2022
- Full Text
- View/download PDF
17. Current concepts related to hypertrophic scarring in burn injuries
- Author
-
Chiang, Ryan S, Borovikova, Anna A, King, Kassandra, Banyard, Derek A, Lalezari, Shadi, Toranto, Jason D, Paydar, Keyianoosh Z, Wirth, Garrett A, Evans, Gregory RD, and Widgerow, Alan D
- Subjects
Stem Cell Research ,Physical Injury - Accidents and Adverse Effects ,Regenerative Medicine ,2.1 Biological and endogenous factors ,Aetiology ,Injuries and accidents ,Burns ,Cicatrix ,Hypertrophic ,Compression Bandages ,Humans ,Mechanotransduction ,Cellular ,Pruritus ,Quality of Life ,Stem Cell Transplantation ,Wound Healing ,Clinical Sciences ,Dermatology & Venereal Diseases - Abstract
Scarring following burn injury and its accompanying aesthetic and functional sequelae still pose major challenges. Hypertrophic scarring (HTS) can greatly impact patients' quality of life related to appearance, pain, pruritus and even loss of function of the injured body region. The identification of molecular events occurring in the evolution of the burn scar has increased our knowledge; however, this information has not yet translated into effective treatment modalities. Although many of the pathophysiologic pathways that bring about exaggerated scarring have been identified, certain nuances in burn scar formation are starting to be recognized. These include the effects of neurogenic inflammation, mechanotransduction, and the unique interactions of burn wound fluid with fat tissue in the deeper dermal layers, all of which may influence scarring outcome. Tension on the healing scar, pruritus, and pain all induce signaling pathways that ultimately result in increased collagen formation and myofibroblast phenotypic changes. Exposure of the fat domes in the deep dermis is associated with increased HTS, possibly on the basis of altered interaction of adipose-derived stem cells and the deep burn exudate. These pathophysiologic patterns related to stem cell-cytokine interactions, mechanotransduction, and neurogenic inflammation can provide new avenues of exploration for possible therapeutic interventions.
- Published
- 2016
18. A Call to Arms: Emergency Hand and Upper-Extremity Operations During the COVID-19 Pandemic
- Author
-
Shawn Diamond, MD, Jonathan B. Lundy, MD, Erin L. Weber, MD, PhD, Shadi Lalezari, MD, Gregory Rafijah, MD, Amber Leis, MD, Benjamin L. Gray, MD, MSCE, Ines C. Lin, MD, MSEd, and Ranjan Gupta, MD
- Subjects
Coronavirus ,COVID-19 ,Extremity trauma ,Hand and upper-extremity emergencies ,Replantation ,Surgery ,RD1-811 - Abstract
Purpose: Limited data exist regarding volumetric trends and management of upper-extremity emergencies during periods of social restriction and duress, such as the coronavirus disease 2019 pandemic. We sought to study the effect of shelter-in-place orders on emergent operative upper-extremity surgery. Methods: All patients undergoing emergent and time-sensitive operations to the finger(s), hand, wrist, and forearm were tracked over an equal number of days before and after shelter-in-place orders at 2 geographically distinct Level I trauma centers. Surgical volume and resources, patient demographics, and injury patterns were compared before and after official shelter-in-place orders. Results: A total of 58 patients underwent time-sensitive or emergent operations. Mean patient age was 42 years; mean injury severity score was 9 and median American Society of Anesthesiologist score was 2. There was a 40% increase in volume after shelter-in-place orders, averaging 1.4 cases/d. Indications for surgery included high-energy closed fracture (60%), traumatic nerve injury (19%), severe soft tissue infection (15%), and revascularization of the arm, hand, or digit(s) (15%). High-risk behavior, defined as lawlessness, assault, and high-speed auto accidents, was associated with a significantly greater proportion of operations after shelter-in-place orders (40% vs 12.5%; P < .05). Each institution dedicated an average of 3 inpatient beds and one intensive care unit–capable bed to upper-extremity care daily. Resources used included an average of 115 minutes of daily operating room time and 8 operating room staff or personnel per case. Conclusions: Hand and upper-extremity operative volume increased after shelter-in-place orders at 2 major Level I trauma centers across the country, demanding considerable hospital resources. The rise in volume was associated with an increase in high-risk behavior. Type of study/level of evidence: Therapeutic IV.
- Published
- 2020
- Full Text
- View/download PDF
19. Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
- Author
-
Lalezari, Shadan, Acquadro, Michaël, de Bock, Elodie, Lambert, Jérémy, and Simpson, Mindy L.
- Published
- 2020
- Full Text
- View/download PDF
20. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
- Author
-
Anagnostou, Valsamo, Niknafs, Noushin, Marrone, Kristen, Bruhm, Daniel C., White, James R., Naidoo, Jarushka, Hummelink, Karlijn, Monkhorst, Kim, Lalezari, Ferry, Lanis, Mara, Rosner, Samuel, Reuss, Joshua E., Smith, Kellie N., Adleff, Vilmos, Rodgers, Kristen, Belcaid, Zineb, Rhymee, Lamia, Levy, Benjamin, Feliciano, Josephine, Hann, Christine L., Ettinger, David S., Georgiades, Christos, Verde, Franco, Illei, Peter, Li, Qing Kay, Baras, Alexander S., Gabrielson, Edward, Brock, Malcolm V., Karchin, Rachel, Pardoll, Drew M., Baylin, Stephen B., Brahmer, Julie R., Scharpf, Robert B., Forde, Patrick M., and Velculescu, Victor E.
- Published
- 2020
- Full Text
- View/download PDF
21. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
- Author
-
Lalezari, Shadi, Chou, Arthur P, Tran, Anh, Solis, Orestes E, Khanlou, Negar, Chen, Weidong, Li, Sichen, Carrillo, Jose A, Chowdhury, Reshmi, Selfridge, Julia, Sanchez, Desiree E, Wilson, Ryan W, Zurayk, Mira, Lalezari, Jonathan, Lou, Jerry J, Ormiston, Laurel, Ancheta, Karen, Hanna, Robert, Miller, Paul, Piccioni, David, Ellingson, Benjamin M, Buchanan, Colin, Mischel, Paul S, Nghiemphu, Phioanh L, Green, Richard, Wang, He-Jing, Pope, Whitney B, Liau, Linda M, Elashoff, Robert M, Cloughesy, Timothy F, Yong, William H, and Lai, Albert
- Subjects
Humans ,Glioblastoma ,Brain Neoplasms ,Dacarbazine ,DNA Repair Enzymes ,DNA Modification Methylases ,Tumor Suppressor Proteins ,DNA ,Neoplasm ,Antineoplastic Agents ,Alkylating ,Neoplasm Staging ,Prognosis ,Survival Rate ,Retrospective Studies ,Follow-Up Studies ,Polymerase Chain Reaction ,DNA Methylation ,Adult ,Middle Aged ,Female ,Male ,Promoter Regions ,Genetic ,Chemoradiotherapy ,Temozolomide ,Cancer ,Brain Disorders ,Neurosciences ,Brain Cancer ,Rare Diseases ,Genetics ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,biomarker ,glioblastoma ,immunohistochemistry ,methylation ,MGMT ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundPromoter methylation of the DNA repair gene, O-6-methylguanine-DNA methyltransferase (MGMT), is associated with improved treatment outcome for newly diagnosed glioblastoma (GBM) treated with standard chemoradiation. To determine the prognostic significance of MGMT protein expression as assessed by immunohistochemistry (IHC) and its relationship with methylation, we analyzed MGMT expression and promoter methylation with survival in a retrospective patient cohort.MethodsWe identified 418 patients with newly diagnosed GBM at University of California Los Angeles Kaiser Permanente Los Angeles, nearly all of whom received chemoradiation, and determined MGMT expression by IHC, and MGMT promoter methylation by methylation-specific PCR (MSP) and bisulfite sequencing (BiSEQ) of 24 neighboring CpG sites.ResultsWith use of the median percentage of cells staining by IHC as the threshold, patients with
- Published
- 2013
22. COSMC mutations reduce T‐synthase activity in advanced Alzheimer's disease
- Author
-
Seema Gollamudi, Rukmani Lekhraj, Shirin Lalezari, and Parviz Lalezari
- Subjects
brain ,C1GALT1/T‐synthase ,COSMC/C1GALT1C1 ,late‐onset Alzheimer's disease ,mutations ,Neurology. Diseases of the nervous system ,RC346-429 ,Geriatrics ,RC952-954.6 - Abstract
Abstract Introduction Mutations in brain tissues that cumulate with age may contribute to Alzheimer's disease (AD). Abnormal glycoprotein and Tn antigen expression have been demonstrated in AD. We identified C1GALT1C1/COSMC mutations in AD and age‐matched normals without AD. The COSMC coding mutations resulted in a significant reduction in T‐synthase activity in advanced AD cases. Methods Identification of COSMC mutations, Real‐Time Quantitative Reverse Transcription PCR (Q‐RT‐PCR), western blotting, and T‐synthase activity assays. Results COSMC mutations were detected in the promotor, coding region and 3′UTR in AD and normals. COSMC coding mutations demonstrated a correlation with AD progression. T‐synthase levels were significantly elevated in advanced AD compared to AD III (P = 0.03) and normals (P = 0.002). T‐synthase activity in advanced AD {Braak and Braak (B&B) stages V and VI} with COSMC coding mutations was 3‐fold lower than advanced AD without mutations, and 1.3‐fold lower than normal (P = 0.001) and AD B&B stage III (P = 0.01) with coding mutations. Discussion COSMC coding mutations significantly diminished T‐synthase activity in advanced AD, potentially causing defective galactosylation.
- Published
- 2020
- Full Text
- View/download PDF
23. Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
- Author
-
Shadan Lalezari, Assaf A. Barg, Rima Dardik, Jacob Luboshitz, Dalia Bashari, Einat Avishai, and Gili Kenet
- Subjects
hemophilia ,carriers ,women ,pregnancy ,childbirth ,reproduction ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Aim Very little is known regarding reproductive choices, pregnancy, and delivery of women with moderate to severe hemophilia. Our aim was to describe our experience with three hemophiliac women and their journey to achieve motherhood. Methods Medical charts of women with moderate to severe hemophilia A treated at our center were evaluated. Data regarding choices of conception, pregnancy course, mode of delivery, and pregnancy outcomes were obtained. Results Three women are presented. Whereas patient 1 chose to adopt her first child and later had twins through egg donations and a surrogate mother, patient 2 underwent spontaneous pregnancy and delivered via cesarean section. Patient 3 preferred in vitro fertilization and preimplantation genetic diagnosis to avoid hemophilia and hemophilia carriership in her offspring. Conclusion The appropriate means to achieve parenthood for women with moderate to severe hemophilia should be individualized and requires support of a comprehensive multidisciplinary team.
- Published
- 2021
- Full Text
- View/download PDF
24. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
- Author
-
Sulkowski, Mark S, Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F, Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M, Symonds, William T, Subramanian, G Mani, McHutchison, John G, Rodriguez-Torres, Maribel, and Dieterich, Douglas
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Emerging Infectious Diseases ,Liver Disease ,Clinical Research ,Digestive Diseases ,Hepatitis - C ,Genetics ,Clinical Trials and Supportive Activities ,HIV/AIDS ,Infectious Diseases ,Hepatitis ,Chronic Liver Disease and Cirrhosis ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Administration ,Oral ,Adult ,Aged ,Antiviral Agents ,Coinfection ,Drug Administration Schedule ,Drug Therapy ,Combination ,Female ,Genotype ,HIV Infections ,Hepacivirus ,Hepatitis C ,Humans ,Male ,Middle Aged ,RNA ,Viral ,Ribavirin ,Sofosbuvir ,Treatment Outcome ,Uridine Monophosphate ,Viral Load ,Young Adult ,PHOTON-1 Investigators ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceTreatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon.ObjectiveTo determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in patients with HCV-HIV coinfection receiving sofosbuvir and ribavirin treatment.Design, setting, and participantsOpen-label, nonrandomized, uncontrolled phase 3 trial conducted at 34 treatment centers in the United States and Puerto Rico (August 2012-November 2013) evaluating treatment with sofosbuvir and ribavirin among patients with HCV genotypes 1, 2, or 3 and concurrent HIV. Patients were required to be receiving ART with HIV RNA values of 50 copies/mL or less and a CD4 T-cell count of more than 200 cells/μL or to have untreated HIV infection with a CD4 T-cell count of more than 500 cells/μL. Of the treatment-naive patients, 114 had HCV genotype 1 and 68 had HCV genotype 2 or 3, and 41 treatment experienced participants who had been treated with peginterferon-ribavirin had HCV genotype 2 or 3, for a total of 223 participants.InterventionsTreatment-naive patients with HCV genotype 2 or 3 received 400 mg of sofosbuvir and weight-based ribavirin for 12 weeks and treatment-naive patients with HCV genotype 1 and treatment-experienced patients with HCV genotype 2 or 3 received the same treatment for 24 weeks.Main outcomes and measuresThe primary study outcome was the proportion of patients with SVR (serum HCV
- Published
- 2014
25. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
- Author
-
Piccioni, David E, Selfridge, Julia, Mody, Reema R, Chowdhury, Reshmi, Li, Sichen, Lalezari, Shadi, Wawrzynski, James, Quan, Jennifer, Zurayk, Mira, Chou, Arthur P, Sanchez, Desiree E, Liau, Linda M, Ellingson, Benjamin M, Pope, Whitney B, Nghiemphu, Phioanh L, Green, Richard M, Wang, He-Jing, Yong, William H, Elashoff, Robert, Cloughesy, Timothy F, and Lai, Albert
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Rare Diseases ,Minority Health ,Neurosciences ,Brain Disorders ,Health Disparities ,Brain Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Angiogenesis Inhibitors ,Antibodies ,Monoclonal ,Humanized ,Bevacizumab ,Brain Neoplasms ,Cohort Studies ,Disease-Free Survival ,Female ,Glioblastoma ,Humans ,Male ,Middle Aged ,Neoplasm Recurrence ,Local ,Retrospective Studies ,Survival Analysis ,Treatment Outcome ,bevacizumab ,recurrent glioblastoma ,retrospective study ,treatment continuation ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundThe optimal timing to initiate bevacizumab (BV) therapy for recurrent glioblastoma (GBM) is currently unclear. To address this issue, we examined progression-free survival (PFS) and survival time (ST) in a large retrospective cohort of GBM patients treated with BV at different recurrences.MethodsWe identified 468 primary GBM patients who underwent biopsy or surgery followed by radiation therapy and temozolomide (RT/TMZ), and then received BV. PFS and ST were compared between patients stratified by the recurrence that BV was initiated (upfront, first recurrence, second recurrence, or 3+ recurrences). We also examined the effect on PFS and ST of the addition of chemotherapy to BV. In a larger cohort of GBM patients, we determined overall treatment continuation rates at each recurrence and identified variables predictive of inability to continue treatment.ResultsBV PFS was similar for all 3 recurrence groups (median, 4.1 months). There were no differences in BV ST (median, 9.8 months). The addition of chemotherapy to BV improved PFS but not ST. Analysis of treatment continuation rates indicated that the number of patients unable to undergo further treatments is modest, and that patients unable to tolerate BV delay can be identified by age ≥60 years and low extent of resection.ConclusionsDeferred use of bevacizumab is not associated with diminished efficacy. Analysis of treatment continuation rates identified patients who may be unable to delay BV therapy. Our findings suggest that there is a fixed survival after BV initiation and that delayed BV treatment is preferable for most patients.
- Published
- 2014
26. Neuromodulatory nerve regeneration: Adipose tissue‐derived stem cells and neurotrophic mediation in peripheral nerve regeneration
- Author
-
Widgerow, Alan D, Salibian, Ara A, Lalezari, Shadi, and Evans, Gregory RD
- Subjects
Stem Cell Research ,Neurosciences ,Physical Injury - Accidents and Adverse Effects ,Transplantation ,Regenerative Medicine ,5.2 Cellular and gene therapies ,Development of treatments and therapeutic interventions ,Adipose Tissue ,Animals ,Humans ,Mesenchymal Stem Cells ,Nerve Growth Factors ,Nerve Regeneration ,Paracrine Communication ,Peripheral Nerve Injuries ,Peripheral Nerves ,Stem Cell Transplantation ,Tissue Engineering ,Tissue Scaffolds ,adipose tissue ,stem cells ,nerve regeneration ,neurotrophic ,peripheral nerve injury ,Psychology ,Neurology & Neurosurgery - Abstract
Peripheral nerve injury requiring nerve gap reconstruction remains a major problem. In the quest to find an alternative to autogenous nerve graft procedures, attempts have been made to differentiate mesenchymal stem cells into neuronal lineages in vitro and utilize these cellular constructs for nerve regeneration. Unfortunately, this has produced mixed results, with no definitive procedure matching or surpassing traditional nerve grafting procedures. This review presents a different approach to nerve regeneration. The literature was reviewed to evaluate current methods of using adipose-derived stem cells (ADSCs) for peripheral nerve regeneration in in vivo models of animal peripheral nerve injury. The authors present cited evidence for directing nerve regeneration through paracrine effects of ADSCs rather than through in vitro nerve regeneration. The paracrine effects rely mainly, but not solely, on the elaboration of nerve growth factors and neurotrophic mediators that influence surrounding host cells to orchestrate in vivo nerve regeneration. Although this paradigm has been indirectly referred to in a host of publications, few major efforts for this type of neuromodulatory nerve regeneration have been forthcoming. The ADSCs are initially "primed" in vitro using specialized controlled medium (not for neuronal differentiation but for sustainability) and then incorporated into a hydrogel base matrix designed for this purpose. This core matrix is then introduced into a natural collagen-based nerve conduit. The prototype design concepts, evidence for paracrine influences, and regulatory hurdles that are avoided using this approach are discussed.
- Published
- 2013
27. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
- Author
-
Nicholas Agresti, Jacob P. Lalezari, Phillip P. Amodeo, Kabir Mody, Steven F. Mosher, Harish Seethamraju, Scott A. Kelly, Nader Z. Pourhassan, C. David Sudduth, Christopher Bovinet, Ahmed E. ElSharkawi, Bruce K. Patterson, Reejis Stephen, Jonah B. Sacha, Helen L. Wu, Seth A. Gross, and Kush Dhody
- Subjects
Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,Acute respiratory distress syndrome (ARDS) ,Leronlimab (PRO 140) ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Coronavirus disease 2019 (COVID-19) is associated with considerable morbidity and mortality. The number of confirmed cases of infection with SARS-CoV-2, the virus causing COVID-19 continues to escalate with over 70 million confirmed cases and over 1.6 million confirmed deaths. Severe-to-critical COVID-19 is associated with a dysregulated host immune response to the virus, which is thought to lead to pathogenic immune dysregulation and end-organ damage. Presently few effective treatment options are available to treat COVID-19. Leronlimab is a humanized IgG4, kappa monoclonal antibody that blocks C–C chemokine receptor type 5 (CCR5). It has been shown that in patients with severe COVID-19 treatment with leronlimab reduces elevated plasma IL-6 and chemokine ligand 5 (CCL5), and normalized CD4/CD8 ratios. We administered leronlimab to 4 critically ill COVID-19 patients in intensive care. All 4 of these patients improved clinically as measured by vasopressor support, and discontinuation of hemodialysis and mechanical ventilation. Following administration of leronlimab there was a statistically significant decrease in IL-6 observed in patient A (p=0.034) from day 0–7 and patient D (p=0.027) from day 0–14. This corresponds to restoration of the immune function as measured by CD4+/CD8+ T cell ratio. Although two of the patients went on to survive the other two subsequently died of surgical complications after an initial recovery from SARS-CoV-2 infection.
- Published
- 2021
- Full Text
- View/download PDF
28. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab
- Author
-
Sohier Elneil, Jacob P. Lalezari, and Nader Z. Pourhassan
- Subjects
Leronlimab ,Coronavirus-disease-2019-(COVID-19) ,SARS-CoV-2 ,Extracorporeal-membrane-oxygenation-(ECMO) ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The number of confirmed cases of infection with SARS-CoV-2, the virus causing Coronavirus disease 2019 (COVID-19), continues to increase and is associated with substantial morbidity and mortality in virtually every country in the world. Although in the long-term mass vaccinations remains the most promising approach to control the pandemic, evidence suggests that new variants of the virus have emerged that may be able to evade the immune responses triggered by current vaccines. Therefore despite the recent approval of a number of SARS-CoV-2 vaccines there remains considerable urgency for effective treatments for COVID-19. Severe-to-critical COVID-19 has been shown to be associated with a dysregulated host immune response to SARS-CoV-2 with elevated levels of C–C chemokine receptor type 5 (CCR5) ligands including chemokine C–C ligands 3, 4, 5, as well as interleukins 6 and 10. Leronlimab, a CCR5-specific humanised IgG4 monoclonal antibody originally developed for the treatment of HIV has been studied for the treatment of COVID-19. In the TEMPEST trial which compared leronlimab to placebo in subjects with mild-to-moderate COVID-19, a post hoc analysis showed that leronlimab led to improvements from baseline in National Early Warning Score 2 (NEWS2) at Day 14 in the sub-set of people with more severe disease. Data has also been released on a further ongoing, randomized, placebo-controlled phase 3 registrational trial of leronlimab in 394 people with severe-to-critical COVID-19. The results show that Day 28 mortality was reduced (P = 0.0319) in the subset of participants receiving leronlimab plus other pre-specified commonly used COVID-19 treatments including dexamethasone administered as part of their standard of care (SOC) compared to participants receiving placebo plus other pre-specified commonly used COVID-19 treatments including dexamethasone as part of their SOC. Several cases have recently been reported demonstrated that treatment with leronlimab restores immune function and achieves clinical improvement in people with critical COVID-19. Here we report on a further case of a critically ill person who was treated with leronlimab. This person had been on extracorporeal membrane oxygenation (ECMO) for an extended period of time before receiving 4 doses of leronlimab. The male subject received his first dose of leronlimab on Day 79 of hospitalization he was weaned off ECMO by Day 84 and discharged from the ECMO intensive care unit on Day 91.
- Published
- 2021
- Full Text
- View/download PDF
29. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- Author
-
Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., and Kok, Marleen
- Published
- 2019
- Full Text
- View/download PDF
30. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)‐MRI estimates of cerebral blood volume (CBV) in human gliomas
- Author
-
Ellingson, Benjamin M, Zaw, Taryar, Cloughesy, Timothy F, Naeini, Kourosh M, Lalezari, Shadi, Mong, Sandy, Lai, Albert, Nghiemphu, Phioanh L, and Pope, Whitney B
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Brain Cancer ,Rare Diseases ,Neurosciences ,Brain Disorders ,Clinical Research ,Biomedical Imaging ,Cancer ,Aged ,Blood Volume ,Blood Volume Determination ,Brain Neoplasms ,Cerebrovascular Circulation ,Contrast Media ,Data Interpretation ,Statistical ,Glioma ,Humans ,Image Interpretation ,Computer-Assisted ,Magnetic Resonance Imaging ,Middle Aged ,Reproducibility of Results ,Sensitivity and Specificity ,cerebral blood volume ,CBV ,dynamic susceptibility contrast MRI ,DSC ,MRI ,glioma ,brain tumor ,Physical Sciences ,Engineering ,Medical and Health Sciences ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
PurposeTo compare "standardization," "Gaussian normalization," and "Z-score normalization" intensity transformation techniques in dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) estimates of cerebral blood volume (CBV) in human gliomas. DSC-MRI is a well-established biomarker for CBV in brain tumors; however, DSC-MRI estimates of CBV are semiquantitative. The use of image intensity transformation algorithms provides a mechanism for obtaining quantitatively similar CBV maps with the same intensity scaling.Materials and methodsThe coefficient of variance (CV) in normal-appearing white matter and relative contrast between tumor regions and normal tissue was compared between the three CBV transformations across five different MR scanners in 96 patients with gliomas.ResultsThe results suggest all normalization techniques improved variability and relative tumor contrast of CBV measurements compared with nonnormalized CBV maps. The results suggest Gaussian normalization of CBV maps provided slightly lower CV in normal white matter and provided slightly higher tumor contrast for glioblastomas (WHO grade IV) compared with other techniques.ConclusionThe results suggest Gaussian normalization of leakage-corrected CBV maps may be the best choice for image intensity correction for use in large-scale, multicenter clinical trials where MR scanners and protocols vary widely due to ease of implementation, lowest variability, and highest tumor to normal tissue contrast.
- Published
- 2012
31. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
- Author
-
Ellingson, Benjamin M, Cloughesy, Timothy F, Zaw, Taryar, Lai, Albert, Nghiemphu, Phioanh L, Harris, Robert, Lalezari, Shadi, Wagle, Naveed, Naeini, Kourosh M, Carrillo, Jose, Liau, Linda M, and Pope, Whitney B
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Cancer ,Rare Diseases ,Brain Cancer ,Clinical Research ,Biotechnology ,Brain Disorders ,4.2 Evaluation of markers and technologies ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Detection ,screening and diagnosis ,Aged ,Brain Neoplasms ,Chemoradiotherapy ,Diffusion Magnetic Resonance Imaging ,Disease Progression ,Disease-Free Survival ,Female ,Glioblastoma ,Humans ,Image Interpretation ,Computer-Assisted ,Male ,Middle Aged ,Prognosis ,Treatment Outcome ,biomarker ,fDMs ,functional diffusion maps ,glioblastoma ,MRT ,Neurosciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
Functional diffusion mapping (fDM) has shown promise as a sensitive imaging biomarker for predicting survival in initial studies consisting of a small number of patients, mixed tumor grades, and before routine use of anti-angiogenic therapy. The current study tested whether fDM performed before and after radiochemotherapy could predict progression-free and overall survival in 143 patients with newly diagnosed glioblastoma from 2007 through 2010, many treated with anti-angiogenic therapy after recurrence. Diffusion and conventional MRI scans were obtained before and 4 weeks after completion of radiotherapy and concurrent temozolomide treatment. FDM was created by coregistering pre- and posttreatment apparent diffusion coefficient (ADC) maps and then performing voxel-wise subtraction. FDMs were categorized according to the degree of change in ADC in pre- and posttreatment fluid-attenuated inversion recovery (FLAIR) and contrast-enhancing regions. The volume fraction of fDM-classified increasing ADC(+), decreasing ADC(-), and change in ADC(+/-) were tested to determine whether they were predictive of survival. Both Bonferroni-corrected univariate log-rank analysis and Cox proportional hazards modeling demonstrated that patients with decreasing ADC in a large volume fraction of pretreatment FLAIR or contrast-enhancing regions were statistically more likely to progress earlier and expire sooner than in patients with a lower volume fraction. The current study supports the hypothesis that fDM is a sensitive imaging biomarker for predicting survival in glioblastoma.
- Published
- 2012
32. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas
- Author
-
Ellingson, Benjamin M, Cloughesy, Timothy F, Pope, Whitney B, Zaw, Taryar M, Phillips, Heidi, Lalezari, Shadi, Nghiemphu, Phioanh L, Ibrahim, Hassana, Naeini, Kourosh M, Harris, Robert J, and Lai, Albert
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Neurosciences ,Cancer ,Brain Cancer ,Genetics ,Brain Disorders ,Rare Diseases ,Brain ,Brain Neoplasms ,DNA Methylation ,DNA Modification Methylases ,DNA Repair Enzymes ,Female ,Glioblastoma ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Promoter Regions ,Genetic ,Tissue Distribution ,Tumor Suppressor Proteins ,Radiogenomics ,MGMT ,GBM ,Tumor location ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Neurology & Neurosurgery ,Biomedical and clinical sciences ,Health sciences - Abstract
Promoter methylation of O6-methylguanine DNA methyltransferase (MGMT) is associated with a favorable prognosis in glioblastoma multiforme (GBM) and has been hypothesized to occur early in tumor transformation of glial cells. Thus, a possible link exists between the site of malignant transformation and MGMT promoter methylation status. Using the Analysis of Differential Involvement (ADIFFI) statistical mapping technique in a total of 358 patients with GBM, we demonstrate that human de novo GBMs occur in a high frequency contiguous with the posterior subventricular zone (SVZ); MGMT promoter methylated GBMs are lateralized to the left hemisphere, while MGMT unmethylated GBMs are lateralized to the right hemisphere; and tumors near the left temporal lobe have a significantly longer overall survival compared with tumors occurring elsewhere, independent of treatment or MGMT methylation status.
- Published
- 2012
33. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab
- Author
-
Ellingson, Benjamin M, Cloughesy, Timothy F, Lai, Albert, Nghiemphu, Phioanh L, Lalezari, Shadi, Zaw, Taryar, Motevalibashinaeini, Kourosh, Mischel, Paul S, and Pope, Whitney B
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Brain Cancer ,Neurosciences ,Brain Disorders ,Rare Diseases ,Biomedical Imaging ,Clinical Research ,Cancer ,Angiogenesis Inhibitors ,Antibodies ,Monoclonal ,Humanized ,Bevacizumab ,Brain Edema ,Brain Mapping ,Brain Neoplasms ,Diagnostic Imaging ,Disease Progression ,Disease-Free Survival ,Glioblastoma ,Humans ,Image Processing ,Computer-Assisted ,Kaplan-Meier Estimate ,Magnetic Resonance Imaging ,Retrospective Studies ,Survival Analysis ,Vascular Endothelial Growth Factor A ,GBM ,Angiogenesis ,DQT2 ,Magnetic resonance imaging ,MRI ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
The purpose of the current study was to quantify the reduction in T2 signal abnormality accompanying administration of the anti-angiogenic drug bevacizumab in recurrent glioblastoma (GBM) patients using a voxel-wise differential quantitative T2 (DQT2) mapping technique. Twenty-six patients with recurrent GBM treated with bevacizumab were scanned before and 4-6 weeks after treatment on a 1.5T clinical MR scanner. Quantitative T2 maps were created from proton density and T2-weighted images acquired using a standard multi-echo fast-spin echo sequence. T2 maps after treatment were co-registered with T2 maps prior to treatment in the same patient, and then voxel-wise subtraction was performed to create DQT2 maps for each patient. Results suggest DQT2 maps allow visualization and quantification of voxel-wise T2 changes resulting from anti-VEGF therapy. Results demonstrated a significant decrease in T2 within pre-treatment T2 abnormal regions (mean reduction = 49.4 ms at 1.5T) following anti-VEGF treatment (Wilcoxon signed rank test, P < 0.0001). An elevated residual, post-treatment, median T2 was predictive of both progression-free (Log-rank, P = 0.0074) and overall survival (Log-rank, P = 0.0393).
- Published
- 2012
34. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
- Author
-
Mitsuyasu, Ronald T, Merigan, Thomas C, Carr, Andrew, Zack, Jerome A, Winters, Mark A, Workman, Cassy, Bloch, Mark, Lalezari, Jacob, Becker, Stephen, Thornton, Lorna, Akil, Bisher, Khanlou, Homayoon, Finlayson, Robert, McFarlane, Robert, Smith, Don E, Garsia, Roger, Ma, David, Law, Matthew, Murray, John M, von Kalle, Christof, Ely, Julie A, Patino, Sharon M, Knop, Alison E, Wong, Philip, Todd, Alison V, Haughton, Margaret, Fuery, Caroline, Macpherson, Janet L, Symonds, Geoff P, Evans, Louise A, Pond, Susan M, and Cooper, David A
- Subjects
Biomedical and Clinical Sciences ,Immunology ,HIV/AIDS ,Clinical Trials and Supportive Activities ,Pediatric AIDS ,Gene Therapy ,Genetics ,Clinical Research ,Pediatric ,Infectious Diseases ,6.2 Cellular and gene therapies ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,5.2 Cellular and gene therapies ,6.1 Pharmaceuticals ,Infection ,Adult ,Antigens ,CD34 ,Base Sequence ,Double-Blind Method ,Female ,Genetic Therapy ,HIV Infections ,HIV-1 ,Humans ,Male ,Placebos ,RNA ,Catalytic ,Viral Load ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
Gene transfer has potential as a once-only treatment that reduces viral load, preserves the immune system and avoids lifetime highly active antiretroviral therapy. This study, which is to our knowledge the first randomized, double-blind, placebo-controlled, phase 2 cell-delivered gene transfer clinical trial, was conducted in 74 HIV-1-infected adults who received a tat-vpr-specific anti-HIV ribozyme (OZ1) or placebo delivered in autologous CD34+ hematopoietic progenitor cells. There were no OZ1-related adverse events. There was no statistically significant difference in viral load between the OZ1 and placebo group at the primary end point (average at weeks 47 and 48), but time-weighted areas under the curve from weeks 40-48 and 40-100 were significantly lower in the OZ1 group. Throughout the 100 weeks, CD4+ lymphocyte counts were higher in the OZ1 group. This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product.
- Published
- 2009
35. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
- Author
-
Orkin, Chloe, Molina, Jean-Michel, Cahn, Pedro, Lombaard, Johannes, Supparatpinyo, Khuanchai, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, Lahoulou, Rima, Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, and Inciarte Portillo, Alexy
- Abstract
In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz through to 48 and 96 weeks. Here we report 192-week results from both studies.
- Published
- 2024
- Full Text
- View/download PDF
36. Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
- Author
-
Rima Dardik, Einat Avishai, Shadan Lalezari, Assaf A. Barg, Sarina Levy-Mendelovich, Ivan Budnik, Ortal Barel, Yulia Khavkin, Gili Kenet, and Tami Livnat
- Subjects
hemophilia ,carrier ,X-chromosome inactivation ,non-random ,mutation ,monogenic disease ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Introduction: Hemophilia A (HA) is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency or dysfunction due to F8 gene mutations. HA carriers are usually asymptomatic because their FVIII levels correspond to approximately half of the concentration found in healthy individuals. However, in rare cases, a carrier may exhibit symptoms of moderate to severe HA primarily due to skewed inactivation of her non-hemophilic X chromosome. Aim: The aim of the study was to investigate X-chromosome inactivation (XCI) patterns in HA carriers, with special emphasis on three karyotypically normal HA carriers presenting with moderate to severe HA phenotype due to skewed XCI, in an attempt to elucidate the molecular mechanism underlying skewed XCI in these symptomatic HA carriers. The study was based on the hypothesis that the presence of a pathogenic mutation on the non-hemophilic X chromosome is the cause of extreme inactivation of that X chromosome. Methods: XCI patterns were studied by PCR analysis of the CAG repeat region in the HUMARA gene. HA carriers that demonstrated skewed XCI were further studied by whole-exome sequencing (WES) followed by X chromosome-targeted bioinformatic analysis. Results: All three HA carriers presenting with the moderate to severe HA phenotype due to skewed XCI were found to carry pathogenic mutations on their non-hemophilic X chromosomes. Patient 1 was diagnosed with a frameshift mutation in the PGK1 gene that was associated with familial XCI skewing in three generations. Patient 2 was diagnosed with a missense mutation in the SYTL4 gene that was associated with familial XCI skewing in two generations. Patient 3 was diagnosed with a nonsense mutation in the NKAP gene that was associated with familial XCI skewing in two generations. Conclusion: Our results indicate that the main reason for skewed XCI in our female HA patients was negative selection against cells with a disadvantage caused by an additional deleterious mutation on the silenced X chromosome, thus complicating the phenotype of a monogenic X-linked disease. Based on our study, we are currently offering the X inactivation test to symptomatic hemophilia carriers and plan to expand this approach to symptomatic carriers of other X-linked diseases, which can be further used in pregnancy planning.
- Published
- 2021
- Full Text
- View/download PDF
37. Key Role of Preoperative Recumbent Films in the Treatment of Severe Sagittal Malalignment
- Author
-
Karikari, Isaac O., Lenke, Lawrence G., Bridwell, Keith H., Tauchi, Ryoji, Kelly, Michael P., Sugrue, Patrick A., Bumpass, David B., Elsamadicy, Aladine A., Adogwa, Owoicho, Lalezari, Ramin, Koester, Linda, Blanke, Kathy, and Gum, Jeffrey
- Published
- 2018
- Full Text
- View/download PDF
38. Decreased opioid consumption and enhance recovery with the addition of IV Acetaminophen in colorectal patients: a prospective, multi-institutional, randomized, double-blinded, placebo-controlled study (DOCIVA study)
- Author
-
Aryaie, Amir H., Lalezari, Sepehr, Sergent, Wallace K., Puckett, Yana, Juergens, Christopher, Ratermann, Craig, and Ogg, Cari
- Published
- 2018
- Full Text
- View/download PDF
39. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer: A retrospective study and literature review
- Author
-
Voncken, Francine E. M., Aleman, Berthe M. P., van Dieren, Jolanda M., Grootscholten, Cecile, Lalezari, Ferry, van Sandick, Johanna W., Steinberg, Jeffrey D., and Vegt, Erik
- Published
- 2018
- Full Text
- View/download PDF
40. Optimal endobronchial tool sizes for targeting lung lesions based on 3D modeling.
- Author
-
Torre M Bydlon, Gerrit C Langhout, Ferry Lalezari, Koen J Hartemink, Jasper Nijkamp, Susan G Brouwer de Koning, Sjaak Burgers, Benno H W Hendriks, and Theodoor J M Ruers
- Subjects
Medicine ,Science - Abstract
For patients with suspicious lung lesions found on chest x-ray or CT, endo/trans- bronchial biopsy of the lung is the preferred method for obtaining a diagnosis. With the addition of new screening programs, a higher number of patients will require diagnostic biopsy which will prove even more challenging due to the small size of lesions found with screening. There are many endobronchial tools available on the market today and a wide range of new tools under investigation to improve diagnostic yield. However, there is little information available about the optimal tool size required to reach the majority of lesions, especially peripheral ones. In this manuscript we investigate the percentage of lesions that can be reached for various diameter tools if the tools remain inside the airways (i.e. endobronchial biopsy) and the distance a tool must travel "off-road" (or outside of the airways) to reach all lesions.To further understand the distribution of lung lesions with respect to airway sizes and distances from the airways, six 3D models of the lung were generated. The airways were modeled at two different respiratory phases (inspiration and expiration). Three sets of 1,000 lesions were randomly distributed throughout the lung for each respiratory phase. The simulations showed that the percentage of reachable lesions decreases with increasing tool diameter and decreasing lesion diameter. A 1mm diameter tool will reach
- Published
- 2017
- Full Text
- View/download PDF
41. A radiological classification system for intraneural vascular anomalies: assessment of potential for resection with high-resolution MRI
- Author
-
Prasad, Nikhil K, Chawla, Aditya, Lalezari, Sepehr, de Ruiter, Godard C, Howe, Benjamin M, Amrami, Kimberly K, and Spinner, Robert J
- Published
- 2016
- Full Text
- View/download PDF
42. Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- Author
-
Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., and Kok, Marleen
- Published
- 2019
- Full Text
- View/download PDF
43. Cellular HIV RNA/DNA as biomarkers of inducible virion production
- Author
-
A. Cillo, F. Hong, A. Tsai, A. Irrinki, J. Kaur, J. Lalezari, D. Sloan, J.P. Murry, and J. Mellors
- Subjects
Microbiology ,QR1-502 ,Public aspects of medicine ,RA1-1270 - Published
- 2015
- Full Text
- View/download PDF
44. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
- Author
-
Sterman, Felicia L., Lalezari, Jacob P., Kowalczyk, Ula M., Main, David W., Grant, Edward M., Caro, Luzelena, Manning, Cassie M., and Burke, Rochelle L.
- Published
- 2023
- Full Text
- View/download PDF
45. Pregnancy outcomes in women with a mitral valve prosthesis: A systematic review and meta-analysis
- Author
-
Grashuis, Pepijn, Khargi, Shanti D.M., Veen, Kevin, el Osrouti, Azzeddine, Bemelmans-Lalezari, Shirin, Cornette, Jérôme M.J., Roos-Hesselink, Jolien W., Takkenberg, Johanna J.M., and Mokhles, Mostafa M.
- Abstract
To evaluate the ongoing debate concerning the choice of valve prosthesis for women requiring mitral valve replacement (MVR) and who wish to conceive. Bioprostheses are associated with risk of early structural valve deterioration. Mechanical prostheses require lifelong anticoagulation and carry maternal and fetal risks. Also, the optimal anticoagulation regimen during pregnancy after MVR remains unclear.
- Published
- 2023
- Full Text
- View/download PDF
46. Giant intracardiac blood cyst: assessing the relationship between its formation and previous cardiac surgery
- Author
-
Halim, J., van Schaagen, F.R.N., Riezebos, R.K., and Lalezari, S.
- Published
- 2015
- Full Text
- View/download PDF
47. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
- Author
-
Datsen George Wei, Vicki Chiang, Elizabeth Fyne, Mini Balakrishnan, Tiffany Barnes, Michael Graupe, Joseph Hesselgesser, Alivelu Irrinki, Jeffrey P Murry, George Stepan, Kirsten M Stray, Angela Tsai, Helen Yu, Jonathan Spindler, Mary Kearney, Celsa A Spina, Deborah McMahon, Jacob Lalezari, Derek Sloan, John Mellors, Romas Geleziunas, and Tomas Cihlar
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC50 = 4.5 nM) compared with vorinostat (VOR; EC50 = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC50 = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 µM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART.
- Published
- 2014
- Full Text
- View/download PDF
48. Role of Amino Groups in Formation of Human Lymphocyte-Xenogeneic Erythrocyte Rosettes; A Proposed Mechanism for Antigen Recognition
- Author
-
Lalezari, P., Nehlsen, S. L., Novodoff, J., and Lalezari, I.
- Published
- 1975
49. LR16, a Compound with Potent Effects on the Oxygen Affinity of Hemoglobin, on Blood Cholesterol, and on Low Density Lipoprotein
- Author
-
Lalezari, I., Rahbar, S., Lalezari, P., Fermi, G., and Perutz, M. F.
- Published
- 1988
50. Bronchial Stenosis in Central Pulmonary Tumors Treated With Stereotactic Body Radiation Therapy.
- Author
-
Rijksen, Barbara L.T., Rossi, Maddalena M.G., Walraven, Iris, Stam, Barbara, Knegjens, Joost L., van Diessen, Judi N.A., Lalezari, Ferry, Sonke, Jan-Jakob, and Belderbos, José S.A.
- Abstract
Stereotactic body radiation therapy (SBRT) in lung tumors has an excellent local control due to the high delivered dose. Proximity of the proximal bronchial tree (PBT) to the high dose area may result in pulmonary toxicity. Bronchial stenosis is an adverse event that can occur after high dose to the PBT. Literature on the risk of developing bronchial stenosis is limited. We therefore evaluated the risk of bronchial stenosis for tumors central to the PBT and correlated the dose to the bronchi. Patients with a planning tumor volume (PTV) ≤2 cm from PBT receiving SBRT (8 × 7.5 Gy) between 2015 to 2019 were retrospectively reviewed. Main bronchi and lobar bronchi were manually delineated. Follow-up computed tomography scans were analyzed for bronchial stenosis and atelectasis. Bronchial stenosis was assessed using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAEv4). Patient, tumor, dosimetric factors and survival were evaluated between patients with and without stenosis using uni- and multivariate and Kaplan-Meier analysis. Fifty-one patients were analyzed with a median age of 70 years and World Health Organization (WHO) performance status ≤1 in 92.2%. Median follow-up was 36 months (interquartile range [IQR], 19.6-45.4) and median overall survival 48 months (IQR 21.5-59.3). In 15 patients (29.4%) bronchial stenosis was observed on follow-up computed tomography scan. Grade 1 stenosis was seen in 21.6% (n = 11), grade 2 in 7.8% (n = 4). No grade ≥3 stenosis was observed. Median time to stenosis was 9.6 months (IQR 4.4-19.2). Patients who developed stenosis had significantly larger gross tumor volume with a median of 19 cm
3 (IQR 7.7-63.2) versus 5.2 cm3 (IQR 1.7-11.3, P <.01). Prognostic factors in multivariate analysis for stenosis were age (P =.03; odds ratio [OR] 1.1), baseline dyspnea (P =.02 OR 7.7), and the mean lobar bronchus dose (P =.01; OR 1.1). Low-grade (≤2) lobar bronchial stenosis is a complication in approximately one-third of patients after SBRT for lung tumors with a PTV ≤2 cm from PBT. Prognostic risk factors were age, baseline dyspnea and mean dose on a lobar bronchus. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.